MX2021014350A - Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. - Google Patents
Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.Info
- Publication number
- MX2021014350A MX2021014350A MX2021014350A MX2021014350A MX2021014350A MX 2021014350 A MX2021014350 A MX 2021014350A MX 2021014350 A MX2021014350 A MX 2021014350A MX 2021014350 A MX2021014350 A MX 2021014350A MX 2021014350 A MX2021014350 A MX 2021014350A
- Authority
- MX
- Mexico
- Prior art keywords
- isoindoline
- oxo
- compositions
- methods
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Se proporcionan en la presente compuestos de 1-oxo-isoindolin-5-ca rboxamida que tienen la siguiente estructura: (ver Fórmula) en donde R1, R2, R3, R4 y n son como se definen en la presente, composiciones que comprenden una cantidad eficaz de un compuesto de 1-oxo-isoindolin-5-carboxamida, y métodos para tratar o prevenir trastornos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962855619P | 2019-05-31 | 2019-05-31 | |
PCT/US2020/035043 WO2020243379A1 (en) | 2019-05-31 | 2020-05-29 | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014350A true MX2021014350A (es) | 2022-02-21 |
Family
ID=73551319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014350A MX2021014350A (es) | 2019-05-31 | 2020-05-29 | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. |
Country Status (17)
Country | Link |
---|---|
US (2) | US11306101B2 (es) |
EP (1) | EP3976595A4 (es) |
JP (1) | JP2022534979A (es) |
KR (1) | KR20220016167A (es) |
CN (2) | CN114269729A (es) |
AR (1) | AR119057A1 (es) |
AU (1) | AU2020282748A1 (es) |
BR (1) | BR112021022758A2 (es) |
CA (1) | CA3136753A1 (es) |
CL (1) | CL2021003134A1 (es) |
CO (1) | CO2021015624A2 (es) |
IL (1) | IL288278A (es) |
MX (1) | MX2021014350A (es) |
PE (1) | PE20220569A1 (es) |
SG (1) | SG11202112872YA (es) |
TW (1) | TW202110819A (es) |
WO (1) | WO2020243379A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3976595A4 (en) | 2019-05-31 | 2023-01-04 | Celgene Corporation | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREOF |
CN112679421A (zh) * | 2021-01-04 | 2021-04-20 | 都创(上海)医药科技股份有限公司 | 一种(r)-3-氯吡啶基-2-三氟乙胺盐酸盐的合成方法 |
CA3208313A1 (en) | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
JP2024517808A (ja) * | 2021-05-06 | 2024-04-23 | セルジーン コーポレーション | N-((r)-1-(3-クロロピリジン-2-イル)-2,2,2-トリフルオロエチル)-2-((s)-2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-カルボキサミドによる治療方法 |
EP4352046A1 (en) * | 2021-06-08 | 2024-04-17 | Hangzhou Glubio Pharmaceutical Co., Ltd. | Isoindolinone compounds, and uses thereof |
CN115504963A (zh) * | 2021-06-22 | 2022-12-23 | 苏州开拓药业股份有限公司 | 一种c-Myc蛋白降解剂 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
WO2023244815A1 (en) * | 2022-06-16 | 2023-12-21 | Monte Rosa Therapeutics, Inc. | Molecular glue degraders and methods of using the same |
WO2023244818A1 (en) * | 2022-06-16 | 2023-12-21 | Monte Rosa Therapeutics, Inc. | Molecular glue degraders and methods of using the same |
WO2024027694A1 (zh) * | 2022-08-01 | 2024-02-08 | 苏州开拓药业股份有限公司 | 一种蛋白降解剂 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
MX2008002765A (es) * | 2005-08-31 | 2008-04-07 | Celgene Corp | Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos. |
ZA200901078B (en) * | 2006-08-30 | 2010-06-30 | Celgene Corp | 5-substituted isoindoline compounds |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
WO2017007612A1 (en) * | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
EP3976595A4 (en) | 2019-05-31 | 2023-01-04 | Celgene Corporation | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREOF |
-
2020
- 2020-05-29 EP EP20812650.8A patent/EP3976595A4/en active Pending
- 2020-05-29 MX MX2021014350A patent/MX2021014350A/es unknown
- 2020-05-29 CA CA3136753A patent/CA3136753A1/en active Pending
- 2020-05-29 JP JP2021570866A patent/JP2022534979A/ja active Pending
- 2020-05-29 BR BR112021022758A patent/BR112021022758A2/pt unknown
- 2020-05-29 CN CN202080040212.6A patent/CN114269729A/zh active Pending
- 2020-05-29 AR ARP200101539A patent/AR119057A1/es unknown
- 2020-05-29 PE PE2021001963A patent/PE20220569A1/es unknown
- 2020-05-29 TW TW109117973A patent/TW202110819A/zh unknown
- 2020-05-29 KR KR1020217042866A patent/KR20220016167A/ko unknown
- 2020-05-29 WO PCT/US2020/035043 patent/WO2020243379A1/en unknown
- 2020-05-29 SG SG11202112872YA patent/SG11202112872YA/en unknown
- 2020-05-29 AU AU2020282748A patent/AU2020282748A1/en active Pending
- 2020-05-29 CN CN202210612012.4A patent/CN114957212A/zh active Pending
- 2020-05-29 US US16/887,766 patent/US11306101B2/en active Active
-
2021
- 2021-11-21 IL IL288278A patent/IL288278A/en unknown
- 2021-11-22 CO CONC2021/0015624A patent/CO2021015624A2/es unknown
- 2021-11-24 CL CL2021003134A patent/CL2021003134A1/es unknown
-
2022
- 2022-03-09 US US17/690,921 patent/US20220213115A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022534979A (ja) | 2022-08-04 |
CO2021015624A2 (es) | 2022-02-28 |
CL2021003134A1 (es) | 2022-07-01 |
WO2020243379A1 (en) | 2020-12-03 |
US20220213115A1 (en) | 2022-07-07 |
US11306101B2 (en) | 2022-04-19 |
EP3976595A4 (en) | 2023-01-04 |
CA3136753A1 (en) | 2020-12-03 |
KR20220016167A (ko) | 2022-02-08 |
PE20220569A1 (es) | 2022-04-20 |
BR112021022758A2 (pt) | 2022-03-22 |
AU2020282748A1 (en) | 2021-12-09 |
SG11202112872YA (en) | 2021-12-30 |
AR119057A1 (es) | 2021-11-17 |
EP3976595A1 (en) | 2022-04-06 |
US20200377512A1 (en) | 2020-12-03 |
IL288278A (en) | 2022-01-01 |
CN114957212A (zh) | 2022-08-30 |
TW202110819A (zh) | 2021-03-16 |
CN114269729A (zh) | 2022-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014350A (es) | Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos. | |
EA202092248A1 (ru) | Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими | |
MX2021005714A (es) | Nuevos compuestos heterociclicos. | |
MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
GEP20237506B (en) | Pcsk9 antagonist compounds | |
MX2021001433A (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa. | |
MX2010002258A (es) | Compuestos terapeuticos de isoxazol. | |
MX2020006290A (es) | Dinucleotidos ciclicos como agonistas de sting. | |
MX2021009521A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
MX2021012706A (es) | Inhibidores de dihidroorotato deshidrogenasa. | |
MX2021006695A (es) | Moduladores de trex1. | |
PH12020552207A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
NZ735648A (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
MX2021001471A (es) | Benzimidazoles sustituidos como inhibidores de peptidil arginina deiminasa 4 (pad4). | |
CR20220116A (es) | Compuestos heterocíclicos | |
SG10201806809QA (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
WO2018039077A8 (en) | Therapeutic compounds | |
PH12020552206A1 (en) | Pyrazole derivatives as malt1 inhibitors | |
PH12020552172A1 (en) | Cyclic dinucleotides as sting agonists | |
MX2022006229A (es) | Composiciones y metodos para el tratamiento de resistencia a la insulina. | |
CR20220004A (es) | Nuevos compuestos heterocíclicos | |
ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
PH12020551117A1 (en) | Compositions for preventing or treating uveitis | |
MX2022002470A (es) | Inhibidores de dihidroorotato deshidrogenasa sustituidos con urea. | |
MX2019011558A (es) | Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido). |